Honest Criticisms and Limitations of the STEP-3 Trial
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the STEP-3 semaglutide 2.4 mg + intensive behavioral therapy trial.
7 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 7 of 7 clinical reviews.
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the STEP-3 semaglutide 2.4 mg + intensive behavioral therapy trial.
A detailed methodology breakdown of the STEP-3 trial (semaglutide 2.4 mg + intensive behavioral therapy), covering randomization, blinding, estimand framework, inclusion criteria, and how each design choice shapes clinical interpretation.
Deep-dive into STEP-3 follow-up and extension findings for semaglutide 2.4 mg plus intensive behavioral therapy, covering weight regain after discontinuation, durability signals, and long-term safety.
Complete breakdown of the STEP-3 trial's primary and secondary endpoints for semaglutide 2.4 mg plus intensive behavioral therapy, including effect sizes, confidence intervals, response distribution, and time-course data.
Deep dive into STEP-3 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg plus intensive behavioral therapy, examining differential responses by age, sex, BMI, race, and baseline cardiometabolic markers.
A deep-dive overview of the STEP-3 trial (2021): semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% weight loss vs 5.7% with placebo plus IBT at 68 weeks in adults with overweight or obesity.
How the STEP-3 trial of semaglutide 2.4 mg plus intensive behavioral therapy reshapes prescribing decisions, guideline recommendations, and real-world obesity management protocols.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.